# FDA 483 - Xinxiang Tuoxin Pharmaceutical Co. Ltd - June 06, 2019

Source: https://www.globalkeysolutions.net/records/483/xinxiang-tuoxin-pharmaceutical-co-ltd/8eff03f5-2bc3-4e9a-95ce-4be2647445c7

> FDA 483 for Xinxiang Tuoxin Pharmaceutical Co. Ltd on June 06, 2019. Product: drugs. Access full analysis and detailed observations.

---

## Details

- Record Type: 483
- Company Name: Xinxiang Tuoxin Pharmaceutical Co. Ltd
- Inspection Date: 2019-06-06
- Product Type: drugs
- Office Name: Office of Biological Products Operations - Division I
- Summary: An FDA inspection of Xinxiang Tuoxin Pharmaceutical Co., Ltd in Xinxiang, China, revealed significant deficiencies across multiple areas of their operations. The firm failed to adequately establish impurity profiles, validate analytical methods, ensure data integrity in computerized systems, and properly handle product quality complaints. These observations indicate a need for improved quality control and adherence to good manufacturing practices.

## Related Documents

- [483 - 2021-10-18](https://www.globalkeysolutions.net/records/483/xinxiang-tuoxin-pharmaceutical-co-ltd/e3cddd0f-9c6a-43cd-b158-071155413a75)

## Related Officers

- [Compliance Officer](https://www.globalkeysolutions.net/people/yasamin-ameri/73021772-c960-4c65-aa30-cb490866ee58)

Company: https://www.globalkeysolutions.net/companies/xinxiang-tuoxin-pharmaceutical-co-ltd/ba373358-5a25-46e6-a497-d61d94d78862

Office: https://www.globalkeysolutions.net/offices/office-of-biological-products-operations-division-i/49c53dac-7724-4c8c-8708-4f5779ea69c1